Selegiline, a Monoamine oxidase B (MAO-B) inhibitor with neuroprotective and antioxidant effects, is utilized for the oral therapy of Parkinson’s disease, Alzheimer’s disease, depression, narcolepsy and cocaine addiction [64]. The gene discussed is MAOB; the disease is early-onset autosomal dominant Alzheimer disease.